It is the C16α hydroxyl, C16α,17α cyclic ketal with butyraldehyde derivative of prednisolone (11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione). Stereoisomerism
Society and culture
Legal status
On 19 May 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Kinpeygo, intended for the treatment of primary immunoglobulin A nephropathy. The applicant for this medicinal product is Calliditas Therapeutics AB. Kinpeygo is a hybrid medicine of Entocort which has been authorised in the EU since 2 April 1992. Kinpeygo contains the same active substance as Entocort but has a different formulation and a different indication.
The Story of Intellectual Disability: An Evolution of Meaning, Understanding, and Public Perception. Brookes Publishing. Smith, Philip. (2010). Whatever Happened to Inclusion? : The Place of Students with Intellectual Disabilities in Education. New York: Peter Lang Publishing. ISBN 978-1433104343 LCCN 2009-44580 OCLC 460711867. External links

Facts about intellectual disabilities from the US Centers for Disease Controls National Center on Birth Defects and Developmental Disabilities